Overview

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
0
Participant gender:
All
Summary
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight. Important virus-specific factors include HCV genotype and serum HCV RNA level. Finally, important treatment-related factors include the type of interferon, dose of ribavirin and the duration and adherence to treatment. Despite the importance of patient- and virus-specific factors, the most important indicator of treatment success is a rapid, profound and sustained decrease in serum HCV RNA levels after the start of treatment. The on-treatment virological response can thus be used to predict the probability that a given patient will achieve an SVR if they remain on therapy. It can also be used to individualize the duration of treatment. In this study, treatment for patients with chronic hepatitis C was individualized on the basis of clinical characteristics and the on-treatment virological response. The aim was to investigate the usefulness of undetectable HCV RNA levels at week 4 (RVR) and 12 in tailoring the duration of treatment and predicting SVR in Chinese patients with chronic hepatitis C.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Beijing Ditan Hospital
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin
Criteria
Inclusion Criteria:

- Patients with anti-HCV and HCV RNA positive for at least 6 months

Exclusion Criteria:

- Had a haemoglobin level <100 g/L

- Neutrophil count <1.5 x 109/L

- Platelet count <50 x 109/L

- Decompensated liver cirrhosis or liver disease other than that attributable to chronic
hepatitis C

- Co-infected with hepatitis B virus or human immunodeficiency virus

- Had an autoimmune disease, liver tumour, or severe cardiac disease.